Nadroparin carries a potentially high risk of inducing cutaneous delayed-type hypersensitivity responses.

The high risk associated with nadroparin has been validated in controlled trials, and this emphasizes the singularity of each heparin preparation in terms of allergenicity and that individualized anticoagulation is required.